Zylox-Tonbridge Medical Technology Co., Ltd. announced that the ZYLOX® Penguin Peripheral Venous Stent System, self-developed by the Group, has recently been granted marketing approval by the National Medical Products Administration (the "N NMPA"). ZYLOX® Random Peripheral Venous StENT System is an innovative product developed by the medical-industrial joint effort of the Group in cooperation with the First Affiliated Hospital of Chongqing Medical University. The product has 8 invention patents and is designed for lower limb and pelvic venous return disorders caused by iliac vein compression.

The ZYLOX® engu Peripheral Venous Stents, featuring three major designs of oblique entrance, tapered gradient and integrated structure, is designed to reduce the risk of thrombosis while ensuring alignment with the natural variation of dimension of the blood vessel. The ZYLOX?? Penguin Peripheral Venal Venous Stent System is designed to provide excellent wall adherence and gradual expansion, with a proximal closed-loop structure for strong support and a distal open-loop structure for excellent alignment.

The pre-market clinical trial of the ZYLO X®? Penguin Peripheral Stent System was led by Professor Zhao Yu of the First Affiliated Hospital ofChongqing Medical University. A total of 161 patients from 14 top clinical trial centers across the PRC were enrolled over a period of 10 months, with the target vessel patency rate reaching 100% at 12 months after the procedure.

Such excellent clinical trial results strongly demonstrate the safety and efficacy of this product. Iliac Vein Compression Syndrome ("IVCS") is a blood circulation disorder caused by compression of the iliac veins. The main symptoms include leg pain and swelling, occasionally accompanied by deep vein thrombosis.

Treatment paradigm of IVCS mainly includes medication, surgery and vascular intervention. Currently, interventional therapy using peripheral venous stents has become the main method of treatment for IVCS. As disclosed in the prospectus of the Company dated June 22, 2021, the potential incidence of IVCS in the PRC is expected to reach 2.0 million by 2030; meanwhile, the number of peripheral venous stents interventional procedures is expected to grow at a compound annual growth rate of nearly 50% from 2019 to 2030.

With the launch of the ZYLOX®®? Penguin PeripheralVenous Stent System, the Company believes that it will bring domestic innovative iliac vein compression treatment solutions to patients in the PRC with higher quality and accessibility.